Duration of anticoagulant treatment for idiopathic DVT – is prolonged long enough?

Menno V Huisman and Frederikus A Klok

Disclosures: Menno V Huisman: research grants from the Dutch Healthcare Fund, Boehringer-Ingelheim, Pfizer-BMS and Daiichi-Sankyo. Erik Klok: research grants from Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Daiichi-Sankyo, MSD and Actelion, the Dutch Heart foundation and the Dutch Thrombosis association.

Contributions: Authors equally contributed